• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

图像引导机器人放射外科治疗前列腺癌局限性骨转移患者的安全性和可行性。

Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer.

机构信息

Cyberknife Center Munich Grosshadern, Munich, Germany.

出版信息

Urol Oncol. 2013 May;31(4):455-60. doi: 10.1016/j.urolonc.2011.02.023. Epub 2011 Apr 11.

DOI:10.1016/j.urolonc.2011.02.023
PMID:21481619
Abstract

OBJECTIVE

To determine the safety and feasibility after image-guided single fraction robotic stereotactic radiosurgery (SRS) in patients with bone metastases of prostate cancer.

MATERIALS AND METHODS

Forty patients with 64 bone metastases of prostate cancer were prospectively enrolled in a single center study and underwent 54 consecutive outpatient single session SRS procedures during a 4-year period. F-18 choline PET/CT in addition to standard CT imaging was done prior to SRS in all patients. Nineteen patients were under anti-androgen therapy, 8 patients had undergone chemotherapy before SRS. Overall survival and freedom from local tumor recurrence was analyzed with the Kaplan-Meier method.

RESULTS

Mean follow-up was 14 months (3-48 months). Seventy-five percent of patients had a single bone metastasis. The median tumor volume was 13 cc. The mean prescribed tumor dose was 20.2 Gy (16.5-22 Gy). Eight patients had died at the time point of the data analysis. The actuarial 6-months, 12-months, and 24-months local tumor control rate was 95.5% (95% CI: 83.0-98.8) as measured by MRI and PET CT imaging. The median initial PSA before SRS was 5.4 ng/dl (CI: 1.4-8.2) and dropped to 2.7 ng/dl (CI: 0.14-10) after 3 months. One case of progressive neurological deficits was documented.

CONCLUSIONS

This first report on single session, image-guided robotic SRS documents a safe, feasible, and patient-friendly treatment option in selected patients with bone metastases of prostate cancer.

摘要

目的

确定前列腺癌骨转移患者行影像引导单次分割机器人立体定向放射外科治疗(SRS)的安全性和可行性。

材料与方法

在单中心研究中,前瞻性纳入了 40 例 64 处前列腺癌骨转移患者,在 4 年期间共进行了 54 例连续的门诊单次 SRS 治疗。所有患者均在 SRS 前行 F-18 胆碱 PET/CT 结合标准 CT 成像。19 例患者接受抗雄激素治疗,8 例患者在 SRS 前接受过化疗。采用 Kaplan-Meier 法分析总生存期和局部肿瘤无复发生存率。

结果

中位随访时间为 14 个月(3-48 个月)。75%的患者仅有单个骨转移灶,肿瘤体积中位数为 13cc,中位肿瘤处方剂量为 20.2Gy(16.5-22Gy)。在数据分析时,8 例患者已死亡。MRI 和 PET CT 影像学评估的 6 个月、12 个月和 24 个月局部肿瘤控制率的累积生存率分别为 95.5%(95%可信区间:83.0-98.8)。SRS 前初始 PSA 的中位数为 5.4ng/dl(可信区间:1.4-8.2),3 个月后降至 2.7ng/dl(可信区间:0.14-10)。记录到 1 例进行性神经功能缺损病例。

结论

这是首例关于单次分割、影像引导机器人 SRS 的报告,证明了在选择的前列腺癌骨转移患者中,这是一种安全、可行且对患者友好的治疗选择。

相似文献

1
Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer.图像引导机器人放射外科治疗前列腺癌局限性骨转移患者的安全性和可行性。
Urol Oncol. 2013 May;31(4):455-60. doi: 10.1016/j.urolonc.2011.02.023. Epub 2011 Apr 11.
2
[First results of PET / CT-guided secondary lymph node surgery on patients with a PSA relapse after radical prostatectomy].[前列腺癌根治术后前列腺特异抗原复发患者PET/CT引导下二次淋巴结手术的初步结果]
Aktuelle Urol. 2009 Sep;40(5):294-9. doi: 10.1055/s-0028-1098914. Epub 2009 Jun 16.
3
Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer.机器人图像引导的立体定向放射治疗,用于孤立性复发性原发性、淋巴结或转移性前列腺癌。
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):889-97. doi: 10.1016/j.ijrobp.2010.11.031. Epub 2011 Jan 27.
4
Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients.结直肠癌肝转移患者的无框架单次机器人放射外科手术。
Eur J Cancer. 2010 Apr;46(6):1026-32. doi: 10.1016/j.ejca.2010.01.008. Epub 2010 Feb 12.
5
Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy.挽救性立体定向体部放疗治疗局限性前列腺癌转移患者:延迟雄激素剥夺治疗。
Clin Genitourin Cancer. 2013 Mar;11(1):27-32. doi: 10.1016/j.clgc.2012.08.003. Epub 2012 Sep 24.
6
Prognostic Value of [F]-Fluoromethylcholine Positron Emission Tomography/Computed Tomography Before Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.氟[F]-甲基胆碱正电子发射断层扫描/计算机断层扫描对寡转移前列腺癌立体定向体部放疗前的预后价值。
Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):406-410. doi: 10.1016/j.ijrobp.2018.02.005. Epub 2018 Feb 13.
7
Feasibility, safety, and outcome of frameless image-guided robotic radiosurgery for brain metastases.无框架图像引导机器人放射外科治疗脑转移瘤的可行性、安全性和结果。
J Neurooncol. 2010 Apr;97(2):267-74. doi: 10.1007/s11060-009-0023-1. Epub 2009 Oct 4.
8
Stereotactic radiosurgery with or without whole brain radiotherapy for patients with a single radioresistant brain metastasis.立体定向放射外科手术联合或不联合全脑放疗治疗单一耐放射脑转移瘤患者。
Am J Clin Oncol. 2010 Feb;33(1):70-4. doi: 10.1097/COC.0b013e31819ccc8c.
9
CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases.CyberKnife 立体定向放射外科和立体定向消融放疗治疗前列腺癌骨转移患者。
Neoplasma. 2016;63(2):304-12. doi: 10.4149/218_150807N435.
10
Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.全脑放疗后行立体定向放射外科治疗复发性脑转移瘤患者的生存预后因素分析。
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):303-9. doi: 10.1016/j.ijrobp.2011.06.1987. Epub 2011 Nov 11.

引用本文的文献

1
Stereotactic body radiation therapy to postpone systemic therapy escalation for castration-resistant prostate cancer: A multicenter retrospective analysis.立体定向体部放射治疗延缓去势抵抗性前列腺癌全身治疗升级:一项多中心回顾性分析。
Clin Transl Radiat Oncol. 2023 Dec 8;45:100710. doi: 10.1016/j.ctro.2023.100710. eCollection 2024 Mar.
2
Node Oligorecurrence in Prostate Cancer: A Challenge.前列腺癌中的寡转移复发:一项挑战
Cancers (Basel). 2023 Aug 17;15(16):4159. doi: 10.3390/cancers15164159.
3
Stereotactic ablative radiotherapy for oligometastatic prostate cancer.
立体定向消融放疗治疗寡转移前列腺癌
Rep Pract Oncol Radiother. 2022 Oct 31;27(5):778-786. doi: 10.5603/RPOR.a2022.0088. eCollection 2022.
4
The F-PSMA-1007 PET/CT performance on metastasis status and therapy assessment in oligo-metastasis prostate cancer.F-PSMA-1007 PET/CT在寡转移前列腺癌转移状态及治疗评估中的性能
Front Oncol. 2022 Aug 26;12:935979. doi: 10.3389/fonc.2022.935979. eCollection 2022.
5
Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study.通过液体活检对寡转移前列腺癌患者进行分层:一项试点研究的临床见解
Biomedicines. 2022 Jun 4;10(6):1321. doi: 10.3390/biomedicines10061321.
6
Radiation therapy for oligometastatic bone disease in breast cancer.乳腺癌寡转移骨病的放射治疗
Transl Cancer Res. 2020 Aug;9(8):5096-5101. doi: 10.21037/tcr.2020.01.35.
7
SEOR SBRT-SG stereotactic body radiation therapy consensus guidelines for non-spine bone metastasis.SEOR SBRT-SG 立体定向体部放疗共识指南用于非脊柱骨转移。
Clin Transl Oncol. 2022 Feb;24(2):215-226. doi: 10.1007/s12094-021-02695-6. Epub 2021 Oct 11.
8
Long-Lasting Palliation of Bone Oligometastatic Prostate Cancer After Repeated Stereotactic Body Radiotherapy.重复立体定向体部放疗后骨寡转移前列腺癌的长期姑息治疗
Ochsner J. 2021 Fall;21(3):301-305. doi: 10.31486/toj.20.0132.
9
Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies.寡转移复发性前列腺癌与立体定向体部放疗:我们目前的进展如何?前瞻性研究的系统评价与荟萃分析
Eur Urol Open Sci. 2021 Mar 16;27:19-28. doi: 10.1016/j.euros.2021.02.008. eCollection 2021 May.
10
Radiotherapy of oligometastatic prostate cancer: a systematic review.寡转移前列腺癌的放射治疗:系统评价。
Radiat Oncol. 2021 Mar 9;16(1):50. doi: 10.1186/s13014-021-01776-8.